ezetimibe has been researched along with Coronary Artery Disease in 120 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (30.00) | 29.6817 |
| 2010's | 66 (55.00) | 24.3611 |
| 2020's | 18 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blumenthal, RS; Braun, LT; Grundy, SM; Heidenreich, PA; Lloyd-Jones, D; Orringer, CE; Saseen, JJ; Smith, SC; Sperling, LS; Stone, NJ; Virani, SS | 1 |
| Amarenco, P; Bruckert, E; Charles, H; Giroud, M; Kim, JS; Labreuche, J; Lavallée, PC; Lee, BC; Mahagne, MH; Meseguer, E; Nighoghossian, N; Steg, PG; Vicaut, É | 1 |
| De Sutter, J; François, C; Germonpré, E; Van Calster, L; Willems, AM | 1 |
| Christian Schulze, P; Friedrichs, S; Kerksiek, A; Lütjohann, D; Möbius-Winkler, S; Otto, S; Pörner, TC; Weingärtner, O | 1 |
| Abdennbi, K; Angoulvant, D; Kownator, S; Lebeau, F; Meltz, M; Puymirat, E; Sabouret, P; Schiele, F | 1 |
| Akiyama, Y; Eshima, K; Higo, T; Hironaga, K; Ichi, I; Inoue, S; Kadokami, T; Katsuki, S; Kishimoto, J; Matoba, T; Miyata, K; Mukai, Y; Nagata, T; Nakano, Y; Nakashiro, S; Oi, K; Sadamatsu, K; Suematsu, N; Takase, S; Takemoto, M; Todaka, K; Tsutsui, H; Usui, M; Yamamoto, M | 1 |
| Aker, A; Naoum, I; Saliba, W; Zafrir, B | 1 |
| Glorioso, TJ; Gupta, P; Ho, PM; Kovach, CP; Mesenbring, EC; Schwartz, GG; Waldo, SW | 1 |
| Chen, Z; Jin, J; Li, D; Li, Y; Liu, L; Liu, X; Shan, L; Wang, M; Xu, T; Zhang, W | 1 |
| Abe, S; Hashimoto, R; Hasumi, H; Hirose, S; Inoue, T; Masuyama, T; Numao, T; Sakuma, M; Toyoda, S; Waku, R; Yazawa, H | 1 |
| Broncel, M; Chałubiński, M; Gorzelak-Pabis, P; Jackowska, P; Olszewska-Banaszczyk, M; Wojdan, K; Łuczak, E | 1 |
| Del Aguila, MA; Husain, F; Milam, R; Patel, MY; Shaya, FT; Sing, K | 1 |
| Cho, L | 1 |
| Huerín, M; Lobo, M; Masson, G; Masson, W; Molinero, G; Nogueira, JP; Siniawski, D | 1 |
| Agrawal, H; Albert, MA; Auyoung, M; Choy, HK; Liu, J | 1 |
| Bairey Merz, CN; Jayanna, MB; Robinson, JG; Stone, NJ | 1 |
| Musunuru, K | 1 |
| Ha, K; Han, SH; Jang, AY; Kang, WC; Kim, M; Lee, K; Moon, J; Oh, PC; Suh, SY | 1 |
| Briguori, C; Condorelli, G; De Caterina, R; Lanuti, P; Madonna, R; Manzoli, L; Marchisio, M; Perfetti, M; Renna, FV | 1 |
| Adhyaru, BB; Jacobson, TA | 1 |
| Hayashi, T; Hirayama, A; Hiro, T; Ishihara, M; Kodama, K; Komatsu, S; Matsuoka, H; Saito, S; Takayama, T; Ueda, Y | 2 |
| Ai, XB; Li, L; Wang, F; Wang, J; Yi, XL; Zou, YW | 1 |
| Ballantyne, CM; Birtcher, KK; Daly, DD; DePalma, SM; Lloyd-Jones, DM; Minissian, MB; Morris, PB; Orringer, CE; Smith, SC | 1 |
| Blankenberg, S; Braetz, J; Brunner, FJ; Karakas, M; Kohsiack, R; Ojeda, F; Schnabel, RB; Schofer, N; Schrage, B; Seiffert, M; Sinning, C; Staebe, N; Sydow, K; Waldeyer, C; Westermann, D; Zeller, T | 1 |
| Broncel, M; Gorzelak-Pabiś, P; Jackowska, P; Koter-Michalak, M; Olszewska-Banaszczyk, M; Pytel, E | 1 |
| Demirci, D; Ersan Demirci, D | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamashita, T | 1 |
| Katsimardos, A; Kiouri, E; Kotakos, C; Rallidis, LS | 1 |
| Doyle, M; Moss, S; Rees, D; Tardo, D | 1 |
| Cacciotti, L; Calabrò Md, P; Campolongo, G; Marazzi, G; Massaro, R; Pelliccia, F; Rosano, G; Vitale, C; Volterrani, M | 1 |
| Barrett, HPR; Chan, DC; Ma, L; Ooi, EMM; Parhofer, KG; Waldmann, E; Watts, GF | 1 |
| Endo, H; Kanazawa, M; Kondo, M; Nakamura, A; Nozaki, E; Sato, K; Takahashi, T | 1 |
| Antonsen, L; Hansen, HS; Hougaard, M; Jensen, LO; Junker, A; Maehara, A; Mintz, GS; Thayssen, P | 1 |
| Hattori, E; Hirao, K; Kasano, K; Matsumoto, S; Nakamura, S; Teng, Y; Tokunaga, T; Yamamoto, T; Yonetsu, T; Yoshiwara, H | 1 |
| Boden, WE; Hartigan, PM; Maron, DJ; Neff, DR; Weintraub, WS | 1 |
| Hashimoto, Y; Matsue, Y; Matsumura, A; Suzuki, M; Yoshida, M | 1 |
| Davidson, M | 1 |
| Kaznacheeva, EI; Kheĭmets, GI; Kukharchuk, VV; Liakishev, AA; Miklishanskaia, SV; Vlasik, TN | 1 |
| Dohi, Y; Ishibashi, K; Iwasaki, T; Kihara, Y; Kurisu, S; Mitsuba, N; Shimonaga, T | 1 |
| Berthold, HK; Ekroos, K; Gouni-Berthold, I; Hurme, R; Kauhanen, D; Kleber, ME; Laaksonen, R; März, W; Suoniemi, M; Sylvänne, T; Tarasov, K | 1 |
| Che, W; Liu, B; Wang, H; Yan, H; Zhu, W | 1 |
| Chelladurai, Y; Gudzune, KA; Monroe, AK; Ranasinghe, PD; Robinson, KA; Sharma, R | 1 |
| Ito, H; Kimura, T; Kohno, K; Kubo, M; Miyoshi, T; Morita, H; Nakamura, K; Noda, Y | 1 |
| Bays, H; Li, Y; Louder, A; Mallick, R; Schwab, P | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Ono, T; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Kowalska, B; Krysiak, R; Okopień, B; Żmuda, W | 1 |
| Dohi, K; Fujimoto, N; Ito, M; Masuda, J; Miyahara, M; Nakamura, M; Nakata, T; Nishikawa, M; Nishimura, Y; Sasou, T; Sawai, T; Tanigawa, T; Yamada, T | 1 |
| Golledge, J; Guerrero-Romero, F; Sahebkar, A; Simental-Mendía, LE; Watts, GF | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 3 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Rosen, JB; Shah, AK; Tershakovec, AM | 1 |
| Cacciotti, L; Campolongo, G; Gaudio, C; Marazzi, G; Pelliccia, F; Quattrino, S; Rosano, G; Volterrani, M | 1 |
| Jiang, Y; Li, L; Wang, X; Yao, H; Zhang, J; Zhao, X | 1 |
| Chen, X; Gong, Z; Hao, Y; Li, Y; Liu, J; Qi, Y; Qin, L; Sun, J; Wang, M; Wang, W; Wang, Y; Xie, W; Zhang, Q; Zhao, D; Zhao, F | 1 |
| Broncel, M; Chwatko, G; Jackowska, P; Koter-Michalak, M; Kubalczyk, P; Olszewska-Banaszczyk, M; Pytel, E | 1 |
| Albers, JJ; Fleg, JL; Marcovina, SM; O'Brien, KD; Slee, A | 1 |
| Briguori, C; Calabrò, P; Condorelli, G; De Caterina, R; Madonna, R; Quintavalle, C; Salomone, M; Zimarino, M | 1 |
| Chen, Z; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Lopez, JJ; Skalicka, H; Sonka, M; Wahle, A; Zhang, L | 1 |
| Ardanaz, E; Arriola, L; Balkau, B; Barroso, I; Boeing, H; Burgess, S; Deloukas, P; Forouhi, NG; Franks, PW; Grioni, S; Kaaks, R; Key, TJ; Langenberg, C; Lotta, LA; Luan, J; McCarthy, MI; Navarro, C; Nilsson, PM; O'Rahilly, S; Overvad, K; Palli, D; Panico, S; Perry, JRB; Quirós, JR; Riboli, E; Rolandsson, O; Sacerdote, C; Salamanca, EC; Sattar, N; Savage, DB; Scott, RA; Sharp, SJ; Slimani, N; Spijkerman, AM; Stewart, ID; Tjonneland, A; Tumino, R; van der A, DL; van der Schouw, YT; Wareham, NJ; Willems, SM | 1 |
| Antonsen, L; Hansen, HS; Hougaard, M; Jensen, LO; Junker, A; Thayssen, P; Veien, K | 1 |
| Egashira, K; Eshima, K; Higo, T; Hironaga, K; Ichi, I; Inoue, S; Kadokami, T; Katsuki, S; Kishimoto, J; Matoba, T; Miyata, K; Mukai, Y; Nakashiro, S; Oi, K; Sadamatsu, K; Satoh, S; Suematsu, N; Sunagawa, K; Takase, S; Takemoto, M; Todaka, K; Usui, M; Yamamoto, M | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH | 1 |
| Baena, CP; da Costa, AB; Faria-Neto, JR; Fedato, RA; Gomes, GB; Guarita-Souza, LC; Olandoski, M; Shigueoka, LS; Zazula, AD | 1 |
| Al-Tamimi, O; Bakir, S; Bazargani, N; Binbrek, A; Gopal, R; Shakir, DK; Zubaid, M | 1 |
| Einecke, D | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Abdel-Wahab, M; Geist, V; Herrmann, L; Khattab, AA; Liska, B; Richardt, G; Tölg, R; Westphal, R | 1 |
| Robinson, JG | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Fee, WH | 1 |
| Porat, G | 1 |
| Gandhi, MJ | 1 |
| Böhm, F; Hjemdahl, P; Malmström, RE; Pernow, J; Settergren, M | 1 |
| Böger, R; Eggeling, S; Meinertz, T; Munzel, T; Ostad, MA; Schwedhelm, E; Tschentscher, P; Warnholtz, A; Wenzel, P | 1 |
| Averna, M; Brudi, P; Farnier, M; Johnson-Levonas, AO; Massaad, R; Missault, L; Vandormael, K; Vaverkova, H; Viigimaa, M | 1 |
| Cervera, R; Escárcega, RO; Garcia-Carrasco, M; Jara, LJ | 1 |
| Abletshauser, C; Geisen, U; Hoffmann, MM; Odünc, N; Pütz, G; Schäfer, G; Schewe, T; Siegel, E; Winkler, K | 1 |
| Böhm, F; Kalani, M; Pernow, J; Rydén, L; Settergren, M | 1 |
| Chen, RY; Goodman, SG; Jaffer, S; Langer, A; Leiter, LA; Mendelsohn, AA; Teoh, H; Theriault, L; Tjia, S | 1 |
| Liang, W; Lu, GP; Wu, CF; Yang, H; Yu, Q; Zhang, DD | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Dimmeler, S; Fichtlscherer, S; Kämper, U; Rössig, L; Schmidt-Lucke, C | 1 |
| Carabello, BA | 1 |
| Achkouty, G; Aydanian, H; Azar, M; Azar, RR; Badaoui, G; Harb, S; Kassab, R; Sarkis, A | 1 |
| Breuer, HW | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Jensen, E; Leiter, LA; Shah, A; Tershakovec, AM | 1 |
| Campos, AH; Cavalcanti, AB; de Lemos, JA; Fernandes, JL; Maranhão, RC; Martins, HS; Nicolau, JC; Pesaro, AE; Serrano, CV; Souza, HP | 1 |
| Azar, M; Azar, RR; Badaoui, G; Kassab, R; Sarkis, A; Valentin, E | 1 |
| Parhofer, KG | 1 |
| Endo, T; Fukui, K; Himeno, H; Iwahashi, N; Iwasawa, Y; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okada, K; Sawada, R; Shigemasa, T; Shimizu, M; Shimizu, T; Uchino, K; Umemura, S; Wada, A | 2 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Kawaguchi, R | 1 |
| Asano, R; Hagiwara, N; Seki, A; Sumiyoshi, T; Tobaru, T | 1 |
| Stanek, EJ; Taylor, AJ; Villines, TC | 1 |
| Ahmedani, BK; Canepa Escaro, F; Divine, G; Gamalski, S; Hayek, S; Lanfear, DE; Pladevall, M; Sattar, A; Wells, KE; Williams, LK | 1 |
| Steiner, G | 1 |
| Wierzbicki, AS | 1 |
| Al-Shaer, MH | 1 |
| Sawicki, PT; Weizel, A | 1 |
| von Hodenberg, E | 1 |
| McKenney, JM | 1 |
| Radermecker, RP; Scheen, AJ | 1 |
| Bojunga, S; Dimmeler, S; Fichtlscherer, S; Heeschen, C; Rössig, L; Schmidt-Lucke, C; Zeiher, AM | 1 |
| Arteaga Ll, A; Maiz G, A; Rigotti R, A | 1 |
| Genest, J | 1 |
| Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C | 1 |
| Nicholls, SJ; Tuzcu, EM | 1 |
| Bissonnette, S; Boukas, S; Habib, R; Sampalis, JS | 1 |
| Aronow, WS; Joseph, J; Koka, M | 1 |
| Acton, S; Braun, A; Broschat, KO; Krieger, M; Krul, ES; Napawan, N; Stagliano, N; Yesilaltay, A | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
18 review(s) available for ezetimibe and Coronary Artery Disease
| Article | Year |
|---|---|
High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Secondary Prevention | 2021 |
Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2023 |
Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2020 |
Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Treatment Outcome; Ultrasonography | 2020 |
Coronary Artery Disease.
Topics: Animals; Anticholesteremic Agents; Autoimmunity; Biomarkers; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Genetic Predisposition to Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Periodicals as Topic; Phenotype; Risk Factors | 2020 |
Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl.
Topics: Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Drug Utilization; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2020 |
Treating Coronary Artery Disease: Beyond Statins, Ezetimibe, and PCSK9 Inhibition.
Topics: Anticholesteremic Agents; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors | 2021 |
Role of Non-Statins, LDL-C Thresholds, and Special Population Considerations: A Look at the Updated 2016 ACC Consensus Committee Recommendations.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Clinical Trials as Topic; Consensus; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Assessment | 2017 |
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Young Adult | 2013 |
Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
Topics: Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Omega-3; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Medication Adherence; Niacin; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2014 |
Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Regression Analysis; Serine Endopeptidases; Time Factors | 2015 |
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Genetic Association Studies; Genetic Variation; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Odds Ratio; Polymorphism, Genetic; Proprotein Convertase 9; Receptors, LDL; Risk; Simvastatin | 2016 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke | 2008 |
The need for a different cholesterol lowering drug.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Artery Disease; Ezetimibe; Humans; Hyperlipidemias; Intestinal Absorption | 2003 |
[Optimization of cholesterol reduction principles and clinical results of dual inhibition].
Topics: Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Combinations; Ezetimibe; Germany; Guidelines as Topic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Myocardial Infarction; Practice Patterns, Physicians'; Treatment Outcome | 2005 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
[Intensive cholesterol lowering therapy to reduce cardiovascular risk].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Treatment Outcome | 2006 |
61 trial(s) available for ezetimibe and Coronary Artery Disease
| Article | Year |
|---|---|
Intracranial Hemorrhage in the TST Trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Anticoagulants; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Intracranial Arteriosclerosis; Intracranial Hemorrhages; Ischemic Attack, Transient; Ischemic Stroke; Male; Middle Aged; Predictive Value of Tests; Risk Factors; Secondary Prevention; Young Adult | 2022 |
Changes in lipid lowering medication and lipid levels over time in patients with stable coronary artery disease.
Topics: Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Retrospective Studies | 2023 |
Association between Serum Oxysterols and Coronary Plaque Regression during Lipid-Lowering Therapy with Statin and Ezetimibe: Insights from the CuVIC Trial.
Topics: Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxysterols; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome | 2023 |
The influence of statin monotherapy and statin-ezetimibe combined therapy on FoxP3 and IL 10 mRNA expression in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Ezetimibe; Forkhead Transcription Factors; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Leukocytes, Mononuclear; RNA, Messenger | 2019 |
Effect of Atorvastatin (10 mg) and Ezetimibe (10 mg) Combination Compared to Atorvastatin (40 mg) Alone on Coronary Atherosclerosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Spectroscopy, Near-Infrared; Ultrasonography, Interventional | 2021 |
The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelial Progenitor Cells; Ezetimibe; Female; Flow Cytometry; Humans; Male; Middle Aged; Rosuvastatin Calcium | 2017 |
Effect of Ezetimibe on Stabilization and Regression of Intracoronary Plaque - The ZIPANGU Study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Color; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic | 2017 |
Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; China; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Plaque, Atherosclerotic | 2017 |
Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial.
Topics: Anticholesteremic Agents; Cohort Studies; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Prospective Studies; Renal Insufficiency, Chronic | 2018 |
Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Dietary Supplements; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Single-Blind Method | 2019 |
Influence of Ezetimibe on Plaque Morphology in Patients with ST Elevation Myocardial Infarction Assessed by Optical Coherence Tomography: An OCTIVUS Sub-Study.
Topics: Coronary Artery Disease; Coronary Vessels; Ezetimibe; Humans; Plaque, Atherosclerotic; ST Elevation Myocardial Infarction; Tomography, Optical Coherence | 2020 |
Impact of adding ezetimibe to statin to achieve low-density lipoprotein cholesterol goal (from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation [COURAGE] trial).
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Revascularization; Retrospective Studies; Secondary Prevention; Simvastatin; Treatment Outcome | 2013 |
Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides | 2013 |
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
Topics: Adolescent; Adult; Aged; Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Gastrointestinal Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Young Adult | 2013 |
[Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lipid Metabolism; Male; Middle Aged; Severity of Illness Index; Simvastatin; Treatment Outcome | 2013 |
Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; rho-Associated Kinases; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Vascular Stiffness | 2013 |
Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Pyrroles; Research Design; Treatment Outcome; Ultrasonography, Interventional | 2014 |
Add-on ezetimibe reduces small dense low-density lipoprotein cholesterol levels without affecting absorption of eicosapentaenoic acid in patients with coronary artery disease: a pilot study.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Eicosapentaenoic Acid; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Male; Pilot Projects; Prospective Studies | 2014 |
Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Protocols; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Ultrasonography, Interventional | 2015 |
The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels.
Topics: Adrenal Cortex; Adrenocorticotropic Hormone; Adult; Aged; Anticholesteremic Agents; Cholesterol; Coronary Artery Disease; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Ezetimibe; Follicle Stimulating Hormone; Humans; Hydrocortisone; Luteinizing Hormone; Male; Middle Aged; Rosuvastatin Calcium; Sex Hormone-Binding Globulin; Simvastatin; Steroids; Testis; Testosterone | 2015 |
Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2015 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Double-Blind Method; Ezetimibe; Female; Humans; Hypercholesterolemia; Insulin Resistance; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Obesity, Abdominal; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides | 2015 |
Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease.
Topics: Cholesterol; Coronary Artery Disease; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Single-Blind Method; Treatment Outcome | 2015 |
Effects of Combination of Ezetimibe and Rosuvastatin on Coronary Artery Plaque in Patients with Coronary Heart Disease.
Topics: Aged; C-Reactive Protein; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Interleukin-6; Male; Matrix Metalloproteinase 9; Middle Aged; Plaque, Atherosclerotic; Rosuvastatin Calcium; Ultrasonography, Interventional | 2016 |
Intensive statin therapy, used alone or in combination with ezetimibe, improves homocysteine level and lipid peroxidation to a similar degree in patients with coronary artery diseases.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Rosuvastatin Calcium | 2016 |
Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Prospective Studies; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Relationship of baseline HDL subclasses, small dense LDL and LDL triglyceride to cardiovascular events in the AIM-HIGH clinical trial.
Topics: Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cardiovascular System; Cholesterol, HDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Niacin; Proportional Hazards Models; Simvastatin; Treatment Outcome; Triglycerides | 2016 |
Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Cardiotonic Agents; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Percutaneous Coronary Intervention; Rosuvastatin Calcium; Treatment Outcome | 2016 |
Pathologic Intimal Thickening Plaque Phenotype: Not as Innocent as Previously Thought. A Serial 3D Intravascular Ultrasound Virtual Histology Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Plaque, Atherosclerotic; Severity of Illness Index; Time Factors; Ultrasonography, Interventional; User-Computer Interface | 2017 |
Influence of ezetimibe in addition to high-dose atorvastatin therapy on plaque composition in patients with ST-segment elevation myocardial infarction assessed by serial: Intravascular ultrasound with iMap: the OCTIVUS trial.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Myocardial Infarction; Treatment Outcome; Ultrasonography, Interventional | 2017 |
Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomize
Topics: Acetylcholine; Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug Combinations; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipoproteins, LDL; Male; Middle Aged; Oxysterols; Percutaneous Coronary Intervention; Prospective Studies; Stents; Time Factors; Treatment Outcome | 2017 |
A Randomized Open-Label Trial to Assess the Effect of Plant Sterols Associated with Ezetimibe in Low-Density Lipoprotein Levels in Patients with Coronary Artery Disease on Statin Therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Phytosterols; Prospective Studies; Young Adult | 2017 |
Effect of ezetimibe coadministration with simvastatin in a Middle Eastern population: a prospective, multicentre, randomized, double-blind, placebo-controlled trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Middle East; Prospective Studies; Simvastatin | 2008 |
Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Germany; Humans; Male; Middle Aged; Prevalence; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2008 |
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Topics: Aged; Anticholesteremic Agents; Azetidines; C-Reactive Protein; CD40 Ligand; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Platelet Aggregation; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
Topics: Adult; Aged; Aged, 80 and over; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2009 |
Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fluvastatin; Humans; Indoles; Male; Metabolic Syndrome; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease.
Topics: Aged; Azetidines; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Foot; Forearm; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Laser-Doppler Flowmetry; Lipids; Male; Microcirculation; Simvastatin; Skin; Ultrasonography | 2009 |
[Effects of different statin regimens on lipid profile and serum metalloproteinases in patients with coronary heart disease].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Metalloproteases; Middle Aged; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Young Adult | 2009 |
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult | 2010 |
The SEAS Trial.
Topics: Anticholesteremic Agents; Aortic Valve Stenosis; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2010 |
Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2010 |
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2010 |
Pleiotropic effects of ezetimibe/simvastatin vs. high dose simvastatin.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Synergism; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation; Simvastatin | 2012 |
The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study partici
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2011 |
Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles; Treatment Outcome | 2011 |
Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Paradoxical progression of atherosclerosis related to low-density lipoprotein reduction and exposure to ezetimibe.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Azetidines; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Disease Progression; Ezetimibe; Female; Humans; Male; Risk Factors | 2012 |
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Phytosterols; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy.
Topics: Acetylcholine; Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Endothelium, Vascular; Ezetimibe; Female; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitroprusside; Prospective Studies; Regional Blood Flow; Vasodilator Agents | 2006 |
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Topics: Atorvastatin; Azetidines; Blood Chemical Analysis; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2007 |
Reduction in estimated risk for coronary artery disease after use of ezetimibe with a statin.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Metabolic Syndrome; Middle Aged; Risk | 2007 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
42 other study(ies) available for ezetimibe and Coronary Artery Disease
| Article | Year |
|---|---|
Increased cholesterol absorption is associated with In-stent-restenosis after stent implantation for stable coronary artery disease.
Topics: Cholesterol, LDL; Constriction, Pathologic; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Ezetimibe; Female; Gas Chromatography-Mass Spectrometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Phytosterols; Stents; Triglycerides | 2022 |
Guideline-Directed Low-Density Lipoprotein Cholesterol Management After Acute Ischemic Stroke: Findings from a National Health Care Service.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Delivery of Health Care; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Stroke; Stroke | 2023 |
Projected Outcomes of Optimized Statin and Ezetimibe Therapy in US Military Veterans with Coronary Artery Disease.
Topics: Aged; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; United States; Veterans | 2023 |
Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies | 2023 |
Add-on ezetimibe treatment to low-dose statins vs medium-intensity statin monotherapy in coronary artery disease patients with poorly controlled dyslipidemia.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Cross-Over Studies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Oxidative Stress | 2019 |
A practical approach to the cholesterol guidelines and ASCVD prevention.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Autoimmune Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Primary Prevention; Risk Assessment; Risk Reduction Behavior; Secondary Prevention; Vascular Calcification | 2020 |
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Fo
Topics: Anticholesteremic Agents; Cardiology; Chemoprevention; Cholesterol, LDL; Consensus; Coronary Artery Disease; Enzyme Inhibitors; Ezetimibe; Humans; Hypercholesterolemia; Medication Therapy Management; Sequestering Agents; United States | 2017 |
Lipid Management After First Diagnosis of Coronary Artery Disease: Contemporary Results From an Observational Cohort Study.
Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Secondary Prevention | 2017 |
Comparison of the effects of rosuvastatin monotherapy and atorvastatin-ezetimibe combined therapy on the structure of erythrocyte membranes in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Erythrocyte Membrane; Erythrocytes; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Membrane Fluidity; Middle Aged; Rosuvastatin Calcium; Thiobarbituric Acid Reactive Substances | 2018 |
Lack of accurate evidence on non-statin medication in patients receiving highintensity statin therapy: Re-evaluation of recommendations is needed.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic | 2018 |
Extreme-risk category: High prevalence among stable coronary patients and an emerging widening treatment gap in achieving LDL-cholesterol less than 55 mg/dL.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Down-Regulation; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; PCSK9 Inhibitors; Prevalence; Proprotein Convertase 9; Risk Assessment; Risk Factors; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome | 2018 |
Complex disease management of pregnant young patient with familial hypercholesterolaemia complicated by coronary artery disease and cerebrovascular disease.
Topics: Adult; Anticholesteremic Agents; Cerebrovascular Disorders; Cholesterol, LDL; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Echocardiography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant, Newborn; Magnetic Resonance Angiography; Magnetic Resonance Imaging, Cine; Pregnancy; Pregnancy Complications, Cardiovascular | 2018 |
Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Aspirin; Blood Component Removal; Coronary Artery Disease; Cross-Sectional Studies; Ezetimibe; Female; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation Inhibitors; Young Adult | 2019 |
Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Female; Humans; Hyperlipidemias; Insulin; Insulin Resistance; Linear Models; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Prospective Studies; Triglycerides | 2019 |
Impact of intensively lowered low-density lipoprotein cholesterol on deferred lesion prognosis.
Topics: Aged; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Down-Regulation; Dyslipidemias; Ezetimibe; Female; Fractional Flow Reserve, Myocardial; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Retrospective Studies; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Time-to-Treatment; Treatment Outcome | 2020 |
Effects of ezetimibe on serum polyunsaturated fatty acids in patients with coronary artery disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Ezetimibe; Fatty Acids, Unsaturated; Female; Humans; Male; Middle Aged | 2013 |
Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency.
Topics: Aged; Azetidines; Case-Control Studies; Coronary Artery Disease; Ezetimibe; Female; Follow-Up Studies; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Hypolipidemic Agents; Lipids; Macromolecular Substances; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Randomized Controlled Trials as Topic; Risk Factors; Serine Endopeptidases; Simvastatin | 2014 |
Cholesterol treatment patterns and cardiovascular clinical outcomes associated with colesevelam HCl and ezetimibe.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allylamine; Anticholesteremic Agents; Azetidines; Cohort Studies; Colesevelam Hydrochloride; Coronary Artery Disease; Diagnosis-Related Groups; Ezetimibe; Female; Health Services for the Aged; Humans; Hypercholesterolemia; Male; Middle Aged; Retrospective Studies; Treatment Outcome; United States | 2014 |
[Association between very low density lipoprotein cholesterol and cholesterol absorption/synthesis markers in patients with moderate and high risk of coronary heart disease].
Topics: Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phytosterols; Risk Factors | 2015 |
Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; PCSK9 Inhibitors; Practice Guidelines as Topic | 2017 |
[Dual lipid control without anti-atherosclerosis effect].
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Middle Aged; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Uncertainty dogs Zetia and Vytorin.
Topics: Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Drug Combinations; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin; Uncertainty | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
The ENHANCE trial.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2008 |
Does 'ENHANCE' diminish confidence in ezetimibe?
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Humans; Simvastatin | 2008 |
Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality.
Topics: Aspirin; Azetidines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk | 2009 |
Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Triglycerides | 2009 |
Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Apoptosis; Azetidines; Coronary Artery Disease; Endothelial Cells; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Regeneration; Stem Cells | 2010 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
[After bypass surgery nearly all lipids are in the normal range. However, Lp(a) is too high, what can be done?].
Topics: Azetidines; Cholesterol; Coronary Artery Bypass; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypolipidemic Agents; Indoles; Lipoprotein(a); Male; Postoperative Complications; Prognosis; Reference Values; Risk Factors; Secondary Prevention; Treatment Outcome | 2011 |
Trial clouds use of niacin with a statin.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Delayed-Action Preparations; Drug Therapy, Combination; Endpoint Determination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Simvastatin; Treatment Failure | 2011 |
Low-density lipoprotein cholesterol lowering therapy and established atherosclerosis.
Topics: Atorvastatin; Azetidines; Coronary Artery Disease; Coronary Vessels; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Plaque, Atherosclerotic; Pyrroles | 2012 |
Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Dose-Response Relationship, Drug; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Inflammation; Lipids; Male; Treatment Outcome | 2013 |
Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality.
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cause of Death; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Michigan; Middle Aged; Odds Ratio; Retrospective Studies | 2013 |
Ezetimibe: a new addition to lipid-lowering therapy.
Topics: Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia | 2003 |
The effects of ezetimibe on the LDL-cholesterol particle number.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Humans; Particle Size | 2004 |
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin | 2004 |
Serum plant sterols and atherosclerosis: is there a place for statin-ezetimibe combination?
Topics: Anticholesteremic Agents; Azetidines; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phytosterols; Risk Factors | 2006 |
Statins targeting inflammation by lowering low-density lipoprotein?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2007 |
Prevalence of adequate and of optimal control of serum low-density lipoprotein cholesterol in an academic nursing home.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nursing Homes; Peripheral Vascular Diseases; Risk Assessment; Risk Factors | 2007 |
Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Azetidines; Bile Acids and Salts; Body Weight; Cardiomegaly; Cholesterol; Coronary Artery Disease; Cyclic N-Oxides; Disease Models, Animal; Eating; Ezetimibe; Female; Fibrosis; Hypercholesterolemia; Intestinal Absorption; Life Expectancy; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Scavenger Receptors, Class B; Survival Rate; Triglycerides; Tropanes | 2008 |